Naimish Patel sold $211k of CRSP
Chief Medical Officer at CRISPR Therapeutics AG. 3,786 shares at an average of $55.62, traded May 29, 2026, filed Jun 1, 2026.
Score components
- +15RoleOfficer
- +12Trade size$211k at market
- +5Share of holdings soldSold 16% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-251817, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 28, 2026 | MOption exercise Common Shares | +10,000 | - | - | 23,143 | Jun 1, 2026 |
| May 29, 2026 | SOpen-market sale Common Shares | -3,786 | $55.62 | $211k | 19,357 | Jun 1, 2026 |
| May 28, 2026 | MOption exercise Restricted Stock Unitsderivative | -10,000 | - | - | 20,000 | Jun 1, 2026 |
Related signals
Other insiders at CRISPR Therapeutics AG and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $119k 1,990 shares | -2% | |
| 8Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $626k 10,400 shares | -10% | |
| 40Moderate | CRISPR Therapeutics AG | Ali Behbahani director | $781k 13,679 shares | -45% | |
| 38Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $173k 3,708 shares | -19% | |
| 42Moderate | CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $469k 10,020 shares | -4% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $149k 3,182 shares | -3% | |
| 43Moderate | CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $499k 10,349 shares | -4% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $166k 3,450 shares | -4% | |
| 50Moderate | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $476k 9,869 shares | -42% | |
| 31Weak | CRISPR Therapeutics AG | Naimish Patel Chief Medical Officer | $152k 3,150 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.